Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Konstantinos Kostikas, Timm Greulich, Alexander J. Mackay, Nadine S. Lossi, Maryam Aalamian-Mattheis, Xavier Nunez, Veronica A. Pagano, Francesco Patalano, Andreas Clemens, Claus F. Vogelmeier. Treatment response in COPD: does FEV₁ say it all? A post hoc analysis of the CRYSTAL study. ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018

Member's Comments

No comment yet.

Related content which might interest you: The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Correlation between clinic and remote FEV1 and FeNO measurements; post hoc analysis of the INCONTRO study Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018 Year: 2018 Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial Source: ERJ Open Res, 7 (4) 00418-2021; 10.1183/23120541.00418-2021 Year: 2021 Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies. Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016